Skip to main content

Table 3 Incidence and severity of post-ERCP pancreatitis according to the usage of nafamostat mesilate after matching

From: The effect of nafamostat mesilate infusion after ERCP for post-ERCP pancreatitis

  Nafmostat mesilate (n = 201) Control (n = 106) Total (N = 307) P value
PEP (%) 35 (17.4) 11 (10.3) 46 (15.0) 0.168
 Mild (%) 30 (85.7) 5 (45.5) 35 (76.1) 0.021
 Moderate to severe (%) 5 (14.3) 6 (54.5) 11 (23.9)  
  1. PEP post-ERCP pancreatitis